None
|
Never
|
41/173
|
1.00 (Ref)
| | |
None
|
Ever
|
78/162
|
2.03 (1.32–3.14)
| | |
Any
|
Never
|
76/125
|
2.57 (1.65–4.00)
| | |
Any
|
Ever
|
150/92
|
6.88 (4.48–10.56)
| | |
Interaction
| | | | | |
AP
| | |
0.48 (0.43–0.55)
| | |
RERI
| | |
3.28 (1.43–6.16)
| | |
SI
| | |
2.26 (1.36–3.76)
| | |
MI
| | |
P = 0.35
| | |
| |
Anti-CCP2 positive
|
Anti-CCP2 negative
|
HLA-SE
|
Smoking
|
Cases/controls
|
OR (95% CI)
|
Cases/controls
|
OR (95% CI)
|
None
|
Never
|
10/173
|
1.00 (Ref)
|
31/173
|
1.00 (Ref)
|
None
|
Ever
|
26/162
|
2.77 (1.30–5.94)
|
52/162
|
1.79 (1.09–2.94)
|
Any
|
Never
|
24/125
|
3.32 (1.53–7.19)
|
52/125
|
2.32 (1.41–3.83)
|
Any
|
Ever
|
66/92
|
12.41 (6.09–25.28)
|
84/92
|
5.10 (3.14–8.26)
|
Interaction
| | | | | |
AP
| | |
0.59 (0.53–0.67)
| |
0.39 (0.32–0.50)
|
RERI
| | |
7.31 (3.35–17.90)
| |
1.98 (0.21–4.41)
|
SI
| | |
2.78 (1.49–5.19)
| |
1.94 (1.03–3.66)
|
MI
| | |
P = 0.53
| |
P = 0.55
|
| |
Anti-CCP-1/Fil307-324 positive
|
Anti-CCP-1/Fil307-324 negative
|
HLA-SE
|
Smoking
|
Cases/controls
|
OR (95% CI)
|
Cases/controls
|
OR (95% CI)
|
None
|
Never
|
8/173
|
1.00 (Ref)
|
33/173
|
1.00 (Ref)
|
None
|
Ever
|
18/162
|
2.40 (1.02–5.68)
|
60/162
|
1.94 (1.21–3.13)
|
Any
|
Never
|
24/125
|
4.15 (1.81–9.55)
|
52/125
|
2.18 (1.33–3.57)
|
Any
|
Ever
|
46/92
|
10.81 (4.90–23.88)
|
104/92
|
5.93 (3.72–9.45)
|
Interaction
| | | | | |
AP
| | |
0.49 (0.40–0.60)
| |
0.47 (0.41–0.56)
|
RERI
| | |
5.26 (0.52–15.71)
| |
2.80 (1.02–5.55)
|
SI
| | |
2.15 (1.11–4.16)
| |
2.32 (1.26–4.28)
|
MI
| | |
P = 0.88
| |
P = 0.30
|
| |
Anti-Fibβ36-52 positive
|
Anti-Fibβ36-52 negative
|
HLA-SE
|
Smoking
|
Cases/controls
|
OR (95% CI)
|
Cases/controls
|
OR (95% CI)
|
None
|
Never
|
10/173
|
1.00 (Ref)
|
31/173
|
1.00 (Ref)
|
None
|
Ever
|
22/162
|
2.35 (1.08–5.11)
|
56/162
|
1.93 (1.18–3.14)
|
Any
|
Never
|
22/125
|
3.04 (1.39–6.66)
|
54/125
|
2.41 (1.47–3.97)
|
Any
|
Ever
|
53/92
|
9.97 (4.84–20.51)
|
97/92
|
5.88 (3.65–9.48)
|
Interaction
| | | | | |
AP
| | |
0.56 (0.48–0.66)
| |
0.43 (0.37–0.52)
|
RERI
| | |
5.57 (1.95–14.16)
| |
2.54 (0.68–5.31)
|
SI
| | |
2.64 (1.31–5.34)
| |
2.09 (1.15–3.77)
|
MI
| | |
P = 0.50
| |
P = 0.48
|
| |
Anti-CEP-1/Eno5-21 positive
|
Anti-CEP-1/Eno5-21 negative
|
HLA-SE
|
Smoking
|
Cases/controls
|
OR (95% CI)
|
Cases/controls
|
OR (95% CI)
|
None
|
Never
|
8/173
|
1.00 (Ref)
|
33/173
|
1.00 (Ref)
|
None
|
Ever
|
20/162
|
2.67 (1.14–6.23)
|
58/162
|
1.88 (1.16–3.03)
|
Any
|
Never
|
20/125
|
3.46 (1.47–8.11)
|
56/125
|
2.35 (1.44–3.83)
|
Any
|
Ever
|
54/92
|
12.69 (5.79–27.81)
|
96/92
|
5.47 (3.42–8.75)
|
Interaction
| | | | | |
AP
| | |
0.60 (0.52–0.69)
| |
0.41 (0.34–0.51)
|
RERI
| | |
7.56 (3.14–20.18)
| |
2.24 (0.47–4.77)
|
SI
| | |
2.83 (1.44–5.58)
| |
2.00 (1.10–3.66)
|
MI
| | |
P = 0.54
| |
P = 0.51
|
| |
Anti-Fibβ62-81a (72) positive
|
Anti-Fibβ62-81a ( 72) negative
|
HLA-SE
|
Smoking
|
Cases/controls
|
OR (95% CI)
|
Cases/controls
|
OR (95% CI)
|
None
|
Never
|
2/173
|
1.00 (Ref)
|
39/173
|
1.00 (Ref)
|
None
|
Ever
|
6/162
|
3.20 (0.64–16.10)
|
72/162
|
1.97 (1.26–3.08)
|
Any
|
Never
|
16/125
|
11.07 (2.50–49.02)
|
60/125
|
2.13 (1.34–3.39)
|
Any
|
Ever
|
19/92
|
17.86 (4.07–78.38)
|
131/92
|
6.32 (4.08–9.79)
|
Interaction
| | | | | |
AP
| | |
0.26 (0.02–0.48)
| |
0.51 (0.46–0.59)
|
RERI
| | |
4.59 (–32.49−55.67)
| |
3.21 (1.47–5.96)
|
SI
| | |
1.37 (0.65–2.90)
| |
2.53 (1.42–4.52)
|
MI
| | |
P = 0.45
| |
P = 0.18
|
| |
Anti-Fibβ62-81b (74) positive
|
Anti-Fibβ62-81b (74) negative
|
HLA-SE
|
Smoking
|
Cases/controls
|
OR (95% CI)
|
Cases/controls
|
OR (95% CI)
|
None
|
Never
|
3/173
|
1.00 (Ref)
|
37/173
|
1.00 (Ref)
|
None
|
Ever
|
11/162
|
3.92 (1.07–14.29)
|
66/162
|
1.90 (1.21–3.00)
|
Any
|
Never
|
11/125
|
5.07 (1.39–18.57)
|
65/125
|
2.43 (1.53–3.87)
|
Any
|
Ever
|
32/92
|
20.06 (5.98–67.28)
|
109/92
|
5.54 (3.53–8.69)
|
Interaction
| | | | | |
AP
| | |
0.60 (0.49–0.73)
| |
0.40 (0.33–0.49)
|
RERI
| | |
12.07 (−0.05–53.96)
| |
2.20 (0.47–4.63)
|
SI
| | |
2.72 (1.28–5.79)
| |
1.94 (1.11–3.41)
|
MI
| | |
P = 0.99
| |
P = 0.57
|
| |
Anti-Fibα580-600 positive
|
Anti-Fibα580-600 negative
|
HLA-SE
|
Smoking
|
Cases/controls
|
OR (95% CI)
|
Cases/controls
|
OR (95% CI)
|
None
|
Never
|
4/173
|
1.00 (Ref)
|
36/173
|
1.00 (Ref)
|
None
|
Ever
|
5/162
|
1.34 (0.35–5.06)
|
72/162
|
2.14 (1.36–3.36)
|
Any
|
Never
|
10/125
|
3.46 (1.06–11.28)
|
66/125
|
2.54 (1.59–4.05)
|
Any
|
Ever
|
29/92
|
4.70 (1.44–15.40)
|
131/92
|
6.84 (4.38–10.70)
|
Interaction
| | | | | |
AP
| | |
0.72 (0.60–0.87)
| |
0.46 (0.41–0.54)
|
RERI
| | |
9.84 (3.70–33.71)
| |
3.17 (1.25–6.16)
|
SI
| | |
4.52 (1.37–14.87)
| |
2.19 (1.30–3.67)
|
MI
| | |
P = 0.17
| |
P = 0.45
|
| |
Anti-citC1359-369 positive
|
Anti-citC1359-369 negative
|
HLA-SE
|
Smoking
|
Cases/controls
|
OR (95% CI)
|
Cases/controls
|
OR (95% CI)
|
None
|
Never
|
3/173
|
1.00 (Ref)
|
37/173
|
1.00 (Ref)
|
None
|
Ever
|
11/162
|
3.92 (1.07–14.29)
|
66/162
|
1.90 (1.21–3.00)
|
Any
|
Never
|
7/125
|
3.23 (0.82–12.73)
|
69/125
|
2.58 (1.63–4.09)
|
Any
|
Ever
|
25/92
|
15.67 (4.61–53.29)
|
116/92
|
5.89 (3.77–9.23)
|
Interaction
| | | | | |
AP
| | |
0.61 (0.46–0.77)
| |
0.41 (0.35–0.49)
|
RERI
| | |
9.52 (−1.11–43.03)
| |
2.41 (0.62–4.97)
|
SI
| | |
2.85 (1.16–6.98)
| |
1.97 (1.14–3.39)
|
MI
| | |
P = 0.79
| |
P = 0.56
|
| |
Anti-Vim60-75 positive
|
Anti-Vim60-75 negative
|
HLA-SE
|
Smoking
|
Cases/controls
|
OR (95% CI)
|
Cases/controls
|
OR (95% CI)
|
None
|
Never
|
5/173
|
1.00 (Ref)
|
36/173
|
1.00 (Ref)
|
None
|
Ever
|
6/162
|
1.28 (0.38–4.28)
|
72/162
|
2.14 (1.36–3.36)
|
Any
|
Never
|
13/125
|
3.60 (1.25–10.35)
|
63/125
|
2.42 (1.51–3.87)
|
Any
|
Ever
|
19/92
|
7.14 (2.58–19.76)
|
131/92
|
6.84 (4.38–10.70)
|
Interaction
| | | | | |
AP
| | |
0.46 (0.24–0.70)
| |
0.48 (0.42–0.55)
|
RERI
| | |
3.27 (−2.87–13.75)
| |
3.28 (1.38–6.29)
|
SI
| | |
2.13 (0.72–6.36)
| |
2.28 (1.34–3.88)
|
MI
| | |
P = 0.55
| |
P = 0.37
|
| |
Anti-Fibα563-583 positive
|
Anti-Fibα561-583 negative
|
HLA-SE
|
Smoking
|
Cases/controls
|
OR (95% CI)
|
Cases/controls
|
OR (95% CI)
|
None
|
Never
|
2/173
|
1.00 (Ref)
|
38/173
|
1.00 (Ref)
|
None
|
Ever
|
10/162
|
5.34 (1.15–24.74)
|
68/162
|
1.86 (1.19-2-92)
|
Any
|
Never
|
6/125
|
4.15 (0.82–20.91)
|
71/125
|
2.48 (1.58–3.91)
|
Any
|
Ever
|
21/92
|
19.74 (4.53–86.07)
|
129/92
|
6.22 (4.01–9.64)
|
Interaction
| | | | | |
AP
| | |
0.57 (0.39–0.76)
| |
0.46 (0.41–0.54)
|
RERI
| | |
11.25 (−10.52–71.35)
| |
2.87 (1.10–5.54)
|
SI
| | |
2.50 (1.05–5.95)
| |
2.22 (1.29–3.85)
|
MI
| | |
P = 0.90
| |
P = 0.33
|
| |
Anti-Vim2-17 positive
|
Anti-Vim2-17 negative
|
HLA-SE
|
Smoking
|
Cases/controls
|
OR (95% CI)
|
Cases/controls
|
OR (95% CI)
|
None
|
Never
|
1/173
|
1.00 (Ref)
|
40/173
|
1.00 (Ref)
|
None
|
Ever
|
5/162
|
5.34 (0.62–46.20)
|
73/1162
|
1.95 (1.25–3.03)
|
Any
|
Never
|
2/125
|
2.77 (0.25–30.87)
|
74/125
|
2.56 (1.64–4.01)
|
Any
|
Ever
|
17/92
|
31.97 (4.19–244.04)
|
133/92
|
6.25 (4.05–9.66)
|
Interaction
| | | | | |
AP
| | |
0.77 (0.54–0.99)
| |
0.47 (0.42–0.54)
|
RERI
| | |
24.86 (−16.43–230.81)
| |
2.74 (0.96–5.38)
|
SI
| | |
5.07 (1.42–18.16)
| |
2.02 (1.23–3.54)
|
MI
| | |
P = 0.56
| |
P = 0.45
|
| |
Any ACPA positive
|
Any ACPA negative
|
HLA-SE
|
Smoking
|
Cases/controls
|
OR (95% CI)
|
Cases/controls
|
OR (95% CI)
|
None
|
Never
|
23/173
|
1.00 (Ref)
|
16/173
|
1.00 (Ref)
|
None
|
Ever
|
42/162
|
1.95 (1.12–3.39)
|
35/162
|
2.34 (1.25–4.38)
|
Any
|
Never
|
52/125
|
3.13 (1.82–5.38)
|
25/125
|
2.16 (1.11–4.22)
|
Any
|
Ever
|
88/92
|
7.19 (4.26–12.15)
|
53/92
|
6.23 (3.37–11.51)
|
Interaction
| | | | | |
AP
| | |
0.43 (0.37–0.52)
| |
0.44 (0.35–0.56)
|
RERI
| | |
3.11 (0.77–6.90)
| |
2.73 (0.21–6.81)
|
SI
| | |
2.01 (1.15–3.52)
| |
2.09 (1.02–4.29)
|
MI
| | |
P = 0.65
| |
P = 0.62
|